KWF Dutch Cancer Society Calls
On this page we provide an overview of calls from KWF Dutch Cancer Society.
KWF Pre-announcement: Call Rare Cancer Drug Development
More information will be available in October.
There is an urgent need for better treatment options for people with rare cancers. For that, KWF and other international financing partners will open an international call for the further development of medicines for patients with rare cancer. The focus will be on multinational, multicentre clinical studies (phase 2 or 3) with a good go-to-market strategy.
KWF 2023-2 Exploration
Subsidy: Depends on the project
Deadline: 22 November 2022
Project duration: Up to 4 years.
Consortium: Open to researchers based in a Dutch university, Medical centre or research institute.
Scope: This regular call of the Research & Implementation Program is intended for funding applications within the research phases Basic research and Credentialing:
- Basic research: the goal is to obtain essential insight into the origin and progression of cancer and its (psychosocial) effects, as well as basic principles underlying the prevention and treatment of cancer and relevant technological developments.
- Credentialing: it aims at identifying factors, targets and leads that could influence or improve prevention, diagnostics, treatment and quality of life. Examples are the discovery of drugs or biomarkers and compound or drug screening. The credentialing phase includes a first step towards validating the identified factors, targets or leads.
KWF Call for advancement of biomarkers to daily practice
Subsidy: Between €800,000 and €2M per proposal
Total budget: €5-7M
- Pre-proposal: 13 December 2022
- Full proposal: 11 April 2023
Project duration: Between 2 to 5 years
Consortium: Open to Dutch multidisciplinary consortium, minimum 4 participants, addressing the required variety of disciplines, including e.g., biostatistician, HTA-expert (in-house service/not-for-profit organization). Private partners may be included, and Public Private collaborations are encouraged if co-funding is in place.
Scope: The focus of this call is to bring together the necessary expertise in the field of biomarker research and clinical care, for any cancer type, to reach the next developmental phase of the biomarker candidate(s) on their way to daily practice and to provide the appropriate framework and funding.
This call is open to projects in the modality, pre-clinical or clinical phase:
- Creation of modality phase: The goal is to extensively characterize and further develop new inventions/modalities until there is sufficient (in vitro and in vivo) evidence from model systems or retrospective data and sample sets, to start preparing for human evaluation.
- Preclinical research phase: The goal is the completion of all stages required to start the clinical/human evaluation of a new invention/modality in subjects.
- Clinical research: The goal is to realize prospective clinical research, such as a prospective clinical evaluation of a new invention/modality or assay/tool using a limited number of subjects.
Further reading on the KWF Research & Implementation Programme